Metabolite Card

Formula: C24H40O4 (392.2926)
SMILES: [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(O)=O

Synonyms [en]

Deoxycholic Acid; deoxycholate; Cholerebic; 7alpha-Deoxycholic acid; Desoxycholic acid; 3alpha,12alpha-Dihydroxy-5beta-cholan-24-oic acid

Reviewed

Last reviewed on 2024-06-28.

Cite this Page

Deoxycholic acid. 数据之源,洞见之始. SMRUCC genomics institute, a synthetic life researcher from China. https://biocad_registry.innovation.ac.cn/s/(-)-arctiin (retrieved 2026-01-03) (CAD Registry RN: BioCAD00000009725). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

Note

Deoxycholic acid is a secondary bile acid produced in the liver and is usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, and depends only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine, and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH, and consequently require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135). When present in sufficiently high levels, deoxycholic acid can act as a hepatotoxin, a metabotoxin, and an oncometabolite. A hepatotoxin causes damage to the liver or liver cells. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. An oncometabolite is a compound, when present at chronically high levels, that promotes tumour growth and survival. Among the primary bile acids, cholic acid is considered to be the least hepatotoxic while deoxycholic acid is the most hepatoxic (PMID: 1641875). The liver toxicity of bile acids appears to be due to their ability to peroxidate lipids and to lyse liver cells. High bile acid levels lead to the generation of reactive oxygen species and reactive nitrogen species, disruption of the cell membrane and mitochondria, induction of DNA damage, mutation and apoptosis, and the development of reduced apoptosis capability upon chronic exposure (PMID: 24884764). Chronically high levels of deoxycholic acid are associated with familial hypercholanemia. In hypercholanemia, bile acids, including deoxycholic acid, are elevated in the blood. This disease causes liver damage, extensive itching, poor fat absorption, and can lead to rickets due to lack of calcium in bones. The deficiency of normal bile acids in the intestines results in a deficiency of vitamin K, which also adversely affects clotting of the blood. The bile acid ursodiol (ursodeoxycholic acid) can improve symptoms associated with familial hypercholanemia. Chronically high levels of deoxycholic acid are also associated with several forms of cancer including colon cancer, pancreatic cancer, esophageal cancer, and many other GI cancers.

Entity Information

DBLinks

Other DBLinks
  • CAS Registry Number: 201-478-5
  • CAS Registry Number: 28548-08-5
  • CAS Registry Number: 302-95-4
  • CAS Registry Number: 52745-99-0
  • CAS Registry Number: 566-17-6
  • CAS Registry Number: 73211-10-6
  • CAS Registry Number: 83-44-3
  • CAS Registry Number: 84413-81-0
  • CAS Registry Number: 84413-82-1
  • PubChem: 222528
  • PubChem: 440355
  • ChEBI: ChEBI:28834
  • HMDB: HMDB0000626
  • HMDB: HMDB00626
  • LipidMaps: LMST04010040
  • KEGG: C04483
  • NCBI MeSH: Deoxycholic Acid
  • Wikipedia: Deoxycholic acid
  • Wikipedia: Deoxycholic_acid
  • DrugBank: DB03619
  • RefMet: RM0126048
  • MoNA: BAF_UVA_POS000385
  • MoNA: CCMSLIB00005435450
  • MoNA: CCMSLIB00005435451
  • MoNA: CCMSLIB00005435452
  • MoNA: CCMSLIB00005435507
  • MoNA: CCMSLIB00005435508
  • MoNA: CCMSLIB00005435509
  • MoNA: CCMSLIB00005463896
  • MoNA: CCMSLIB00005463897
  • MoNA: CCMSLIB00005463909
  • MoNA: CCMSLIB00005720571
  • MoNA: CCMSLIB00005720884
  • MoNA: EMBL_MCF_2_0_HRMS_Library000336
  • MoNA: HMDB0000626_ms_ms_852
  • MoNA: HMDB0000626_ms_ms_853
  • MoNA: HMDB0000626_ms_ms_854
  • MoNA: MoNA016848
  • MoNA: MoNA031847
  • MoNA: MoNA031854
  • MoNA: MoNA034656
  • MoNA: MoNA034658
  • MoNA: MoNA034659
  • MoNA: MoNA038095
  • MoNA: MT000137
  • MoNA: NU000151
  • MoNA: NU000152
  • MoNA: NU000153
  • MoNA: NU000154
  • MoNA: NU000155
  • MoNA: PR100932
  • MoNA: PR100933
  • MoNA: PS124001
  • MoNA: PS124002
  • MoNA: PS124007
  • MoNA: PS124008
  • MoNA: PS124009
  • MoNA: PS124010
  • MoNA: PS124011
  • MoNA: PT212400
  • MoNA: PT212403
  • MoNA: TY000188
  • MoNA: VF-NPL-LTQ007118
  • MoNA: VF-NPL-LTQ007119
  • MoNA: VF-NPL-LTQ007120
  • MoNA: VF-NPL-QEHF013882
  • MoNA: VF-NPL-QEHF013883
  • MoNA: VF-NPL-QEHF013884
  • MoNA: VF-NPL-QEHF013885
  • MoNA: VF-NPL-QEHF013886
  • MoNA: VF-NPL-QEHF013887
  • MoNA: VF-NPL-QEHF013888
  • MoNA: VF-NPL-QEHF013889
  • MoNA: VF-NPL-QEHF013890
  • MoNA: VF-NPL-QEHF013891
  • MoNA: VF-NPL-QEHF013892
  • MoNA: VF-NPL-QEHF013893
  • MoNA: VF-NPL-QTOF007376
  • MoNA: VF-NPL-QTOF007377
  • MoNA: VF-NPL-QTOF007378
  • Metlin: METLIN_265
  • Coconut NaturalProduct: CNP0085000.1
  • Coconut NaturalProduct: CNP0085000.2
  • Coconut NaturalProduct: CNP0085000.3
  • Coconut NaturalProduct: CNP0086162.0
  • Coconut NaturalProduct: CNP0170119.1
  • Coconut NaturalProduct: CNP0207602.1
  • Coconut NaturalProduct: CNP0207602.10
  • Coconut NaturalProduct: CNP0207602.3
  • Coconut NaturalProduct: CNP0207602.5
  • Coconut NaturalProduct: CNP0249232.2
  • Coconut NaturalProduct: CNP0572619.0

Class / Ontology

Metabolic Network
ID EC Number Name
KEGG:R04486 3.5.1.24 glycodeoxycholate amidohydrolase
KEGG:R04487 3.5.1.24 taurodeoxycholate amidohydrolase
KEGG:R05836 C11637 + 2 C00080<=>C04483
KEGG:R07220 deoxycholate:FAD oxidoreductase (7alpha-dehydroxylating)
KEGG:R07295 2.8.3.25 deoxycholoyl-CoA:cholate CoA-transferase
View More
Organism Source

Taxonomy Source

  1. Wedelia prostrata [ncbi taxid: ]
  2. Bos taurus domesticus GMELIN [ncbi taxid: ]
  3. Homo sapiens [ncbi taxid: 9606]
  4. Myroides sp. SM1 [ncbi taxid: ]
  5. Penicillium sp. SA29 [ncbi taxid: 445450]
  6. Selenarctos thibetanus [ncbi taxid: ]
  7. Isodon shikokiana var. occidentalis [ncbi taxid: ]

Pathway Synthetic

pathway id name
PathBank:SMP0000808 Inner Membrane Transport
WikiPathways:WP2289 Drug induction of bile acid pathway
WikiPathways:WP3253 Drug induction of bile acid pathway
PathBank:SMP0120468 Congenital Bile Acid Synthesis Defect Type III
PathBank:SMP0000318 Congenital Bile Acid Synthesis Defect Type III
PathBank:SMP0120697 Familial Hypercholanemia (FHCA)
PathBank:SMP0120463 Cerebrotendinous Xanthomatosis (CTX)
PathBank:SMP0120467 Congenital Bile Acid Synthesis Defect Type II
PathBank:SMP0120495 Zellweger Syndrome
PathBank:SMP0000035 Bile Acid Biosynthesis
PathBank:SMP0000314 Congenital Bile Acid Synthesis Defect Type II
PathBank:SMP0000315 Cerebrotendinous Xanthomatosis (CTX)
PathBank:SMP0087329 Bile Acid Biosynthesis
PathBank:SMP0120652 27-Hydroxylase Deficiency
PathBank:SMP0120688 Congenital Bile Acid Synthesis Defect Type III
PathBank:SMP0120477 Familial Hypercholanemia (FHCA)
PathBank:SMP0000317 Familial Hypercholanemia (FHCA)
PathBank:SMP0087236 Bile Acid Biosynthesis
PathBank:SMP0120683 Cerebrotendinous Xanthomatosis (CTX)
PathBank:SMP0120687 Congenital Bile Acid Synthesis Defect Type II
View All Pathways